

CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (cancelled)
2. (currently amended) A method for evaluating the effectiveness of an HIV reverse transcriptase inhibitor as an anti HIV therapy for a patient infected with at least one mutant HIV strain comprising:
 - (i) collecting a sample from an HIV-infected patient;
 - (ii) determining whether the sample comprises a nucleic acid encoding HIV reverse transcriptase having at least one mutation at the position 194, wherein the wild type amino acid is mutated to glycine194G;
 - (iii) correlating the presence of said at least one mutation of step (ii) to a change in effectiveness of said ~~mutated~~-HIV reverse transcriptase inhibitor;
 - (iv) determining of the effectiveness of said ~~mutated~~-HIV reverse transcriptase inhibitor; and
 - (v) comparing the ~~drug~~-effectiveness of said inhibitor in samples containing the said reverse transcriptase mutation, 194G, with samples not containing said mutation.
3. to 4. (cancelled)
5. (currently amended) A method for evaluating a change in ~~an~~-anti HIV drug susceptibility comprising:
 - (i) collecting a sample from an HIV-infected patient;
 - (ii) determining whether the sample comprises an HIV reverse transcriptase having at least one mutation at the position 194, wherein the wild type amino acid is mutated to glycine 194G;
 - (iii) correlating the presence of said at least one mutation of step (ii) to a change in said-anti HIV drug susceptibility;

- (iv) determining the effectiveness of a mutated-reverse transcriptase inhibitor; and
- (v) comparing the anti HIV drug effectiveness in samples containing the said reverse transcriptase mutation, -194G, with samples not containing said mutation.

6. to 10. (cancelled)